Kailera Therapeutics is trading 4.07% down now at $15.55, extending the August 28 decline amid concerns about its wider-than-expected second-quarter loss.
- Its lead obesity candidate has been associated with gastrointestinal side effects, while near-term clinical catalysts remain limited.
- Broader biotech selling and risk reduction ahead of hawkish Federal Reserve commentary are also weighing on the sector.